Nuclear medicine is a crucial medical discipline that significantly enhances patient care by offering non-invasive diagnostic and therapeutic solutions. By employing radiopharmaceuticals and advanced imaging technologies, it enables precise visualisation of organ function and structure. Theranostics, a specific branch of nuclear medicine, integrates diagnostic imaging and targeted therapy by selecting radionuclides based on their properties.
This innovative field combines the terms therapy and diagnostics, reflecting its dual function. This is a significant advancement in medicine, allowing for simultaneous or sequential diagnosis and treatment, to save time and money and mitigate undesirable biological effects associated with separate strategies. Recognising the considerable potential of this pioneering field in revolutionising cancer treatment, the EANM’24 will feature an extensive plenary session entitled ‘The Age of Theranostics’. This session will explore the advancements and prospects of theranostics, highlighting its vital role in personalised cancer care.
Furthermore, the congress will provide extensive continuing medical education opportunities, ensuring attendees remain well-informed of the latest developments. Lastly, there will be a dedicated theranostics track, designed to equip participants with cutting-edge knowledge and practical insights, thus enhancing their capability to apply these innovations in clinical practice.
Beyond the EANM’24, the EANM has established and recently launched a Theranostics Centre of Excellence (CoE) certification. The primary objective of this certification is to ensure a harmonised theranostic approach of the highest quality across various centres. These specialised theranostic centres provide a harmonised approach towards personalised procedures, benefiting foremost patients but also serving other stakeholders, including industry and regulatory authorities.
In addition, the EANM is committed to ensuring continuous education in the field through its ESMIT programme and courses. It currently offers self-paced classes on the fundamentals of research in imaging and theranostics. The forthcoming EANM Focus Meeting 6, to be held in Malta, from January 30 to February 1, 2025, will critically evaluate the impact of imaging on breast cancer care, with a special emphasis on the application of nuclear medicine techniques in various clinical settings. Discussions will include new developments in radiopharmaceuticals and theranostic approaches, underscoring the promising future of breast cancer treatment and diagnosis.
The EANM is steadfast in its dedication to advancing the field of nuclear medicine and theranostics and looks forward to welcoming participants to what promises to be a landmark event in Hamburg, Germany, from October 19 to October 23, 2024.
 which will gather over 7,500 participants worldwide.){kind=link}